DNDi launches child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa
Dans le cadre d’un projet soutenu par la Coopération monégasque, Drugs for Neglected Diseases (DNDi) vient d’obtenir l’approbation des autorités sud-africaines pour la distribution d’un traitement antirétroviral « 4 en 1 » spécialement conçu pour les nourrissons et les jeunes enfants séropositifs. Développé avec la société pharmaceutique internationale Cipla Limited, cette nouvelle combinaison révolutionne l’accès à un traitement facile à utiliser et adapté aux enfants vivant avec le VIH.
©Xavier Vahed-DNDi
This "4-in-1" fixed-dose combination of four antiretroviral that is recommended by the World Health Organization (WHO) has just been aproved by the South African Health Products Regulatory Authority (SAHPRA). This new formulation represents a significant improvement over regular paediatric ARV formulations because it does not require refrigeration, has a sweet taste and is easy to administer to infants and children of different weights and ages, a major improvement for both children and their caregivers over previously available formulations.
As a reminder, the country has 238,000 children under the age of 15 living with HIV – the highest in the world. Worldwide, 2.78 million children and adolescents are living with HIV – 88% of them in sub-Saharan Africa – but only 54% have access to treatment, according to UNICEF.
The 4-in-1 treatment was developed and registered with the financial support of the Monegasque Government, Unitaid, the French Development Agency as well as Swiss and Spanish Development Cooperation agencies, among other partners.
More information : https://dndi.org/press-releases/2022/cipla-dndi-launch-child-friendly-4-in-1-antiretroviral-treatment-young-children-hiv-south-africa/
